Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

@article{Giaccone2004GefitinibIC,
  title={Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.},
  author={Guiseppe Giaccone and Roy S. Herbst and Christian Manegold and Giorgio Scagliotti and Rafael Rosell and Vincent Miller and Ronald B. Natale and Joan Hoff Schiller and Joachim von Pawel and Anna Pluzańska and Ulrich Gatzemeier and John J Grous and Judith S. Ochs and Steven D. Averbuch and Michael K. Wolf and Pamela Rennie and Abderrahim Fandi and David H. Johnson},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2004},
  volume={22 5},
  pages={777-84}
}
PURPOSE The purpose of this study was to determine whether the addition of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington, DE) to standard first-line gemcitabine and cisplatin provides clinical benefit over gemcitabine and cisplatin alone in patients with advanced or metastatic non-small-cell lung cancer (NSCLC). Gefitinib has demonstrated encouraging efficacy in advanced NSCLC in phase II trials in pretreated patients, and a… CONTINUE READING
Highly Influential
This paper has highly influenced 20 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 635 extracted citations

Similar Papers

Loading similar papers…